Bill 54: An Act to Amend the Opioid Damages and Health Care Costs Recovery Act

This bill directly targets companies in the pharmaceutical manufacturing, drug wholesaling, and pharmaceutical consulting industries — particularly those involved in the production, distribution, or promotion of opioid products. Businesses in these sectors, whether operating nationally or with ties to the Northwest Territories, now face potential liability from the federal government in addition to territorial or provincial governments. Day-to-day activities like manufacturing opioid medications, distributing controlled substances to pharmacies or health facilities, or providing consulting advice on opioid products could form the basis of a legal claim. The exposure applies regardless of company size, though large national manufacturers and distributors are the most likely targets given the scale of health care costs at issue.